Congenital adrenal hyperplasia (CAH)
PerkinElmer's Neonatal17 a-OH-Progesterone (17OHP)
assayfor its DELFIA®, AutoDELFIA® and GSP®
platforms platforms provides the highest standardsof reliability
and safety in screening for congenital adrenalhyperplasia (CAH). It
is globally the most widelyused assay for 1st tier CAH screening,
and in 2008 theproduct was used in 47 countries.
No extraction step neededThe assay is a
straightforward dried blood spot assay.No extraction step is
needed, which means savings inboth total assay time and
DELFIA®-technology stands for qualityThe
unique fluorescent properties of lanthanide chelatesare the basis
for high sensitivity and low assayvariation, and these features, in
turn, stand for reliableand accurate 17a-OH-Progesterone
measurement withlow bias.
Early diagnosis for early
diseaseInterventionCongenital adrenal hyperplasia is a
genetic disorderaffecting 1:10,000 to 1:15,000 newborns
worldwideand the most severe form of the disease can lead to
alife-threatening condition during the first weeks of life.The
disease is caused by enzyme defects in the steroidbiosynthesis, the
most frequent types being 21- and11a-hydroxylase deficiency. In
both of these the17a-OH-progesterone, a precursor for cortisol,
isincreased which makes its determination a usefulscreening method
for 95% of all of the CAH cases.
PerkinElmer's Neonatal 17OHP assay is intended for thequantitative
determination of 17a-OH-progesterone indried blood spot specimens
as an aid in screening newbornsfor CAH.